ABBV Quote, Financials, Valuation and Earnings

Biogen has a net margin of -0.15% compared to AbbVie's net margin of 10.87%. AbbVie's return on equity of 61.64% beat Biogen's return on equity of 10.33%.

AbbVie has a consensus price target of $210.51, signalling upside risk potential of 13.08%. On the other hand Biogen has an analysts' consensus of $190.50 which suggests that it could grow by 60.3%. Given that Biogen has higher upside potential than AbbVie, analysts believe Biogen is more attractive than AbbVie.

AbbVie has a beta of 0.554, which suggesting that the stock is 44.574% less volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 3.43%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AbbVie pays 257.71% of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

AbbVie quarterly revenues are $15.1B, which are larger than Biogen quarterly revenues of $2.5B. AbbVie's net income of -$22M is lower than Biogen's net income of $266.7M. Notably, AbbVie's price-to-earnings ratio is 77.53x while Biogen's PE ratio is 10.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 5.86x versus 1.79x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of -0.15% compared to AbbVie's net margin of 19.72%. AbbVie's return on equity of 61.64% beat Gilead Sciences's return on equity of 32.29%.

AbbVie has a consensus price target of $210.51, signalling upside risk potential of 13.08%. On the other hand Gilead Sciences has an analysts' consensus of $113.75 which suggests that it could grow by 10.26%. Given that AbbVie has higher upside potential than Gilead Sciences, analysts believe AbbVie is more attractive than Gilead Sciences.

AbbVie has a beta of 0.554, which suggesting that the stock is 44.574% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 3.43%. Gilead Sciences offers a yield of 3.01% to investors and pays a quarterly dividend of $0.79 per share. AbbVie pays 257.71% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

AbbVie quarterly revenues are $15.1B, which are larger than Gilead Sciences quarterly revenues of $6.7B. AbbVie's net income of -$22M is lower than Gilead Sciences's net income of $1.3B. Notably, AbbVie's price-to-earnings ratio is 77.53x while Gilead Sciences's PE ratio is 21.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 5.86x versus 4.53x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -0.15% compared to AbbVie's net margin of 50.24%. AbbVie's return on equity of 61.64% beat Johnson & Johnson's return on equity of 30.18%.

AbbVie has a consensus price target of $210.51, signalling upside risk potential of 13.08%. On the other hand Johnson & Johnson has an analysts' consensus of $169.84 which suggests that it could grow by 9.87%. Given that AbbVie has higher upside potential than Johnson & Johnson, analysts believe AbbVie is more attractive than Johnson & Johnson.

AbbVie has a beta of 0.554, which suggesting that the stock is 44.574% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 3.43%. Johnson & Johnson offers a yield of 3.21% to investors and pays a quarterly dividend of $1.24 per share. AbbVie pays 257.71% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie's is not.

AbbVie quarterly revenues are $15.1B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. AbbVie's net income of -$22M is lower than Johnson & Johnson's net income of $11B. Notably, AbbVie's price-to-earnings ratio is 77.53x while Johnson & Johnson's PE ratio is 17.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 5.86x versus 4.20x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -0.15% compared to AbbVie's net margin of -117.16%. AbbVie's return on equity of 61.64% beat Moderna's return on equity of -29.09%.

AbbVie has a consensus price target of $210.51, signalling upside risk potential of 13.08%. On the other hand Moderna has an analysts' consensus of $49.96 which suggests that it could grow by 83.55%. Given that Moderna has higher upside potential than AbbVie, analysts believe Moderna is more attractive than AbbVie.

AbbVie has a beta of 0.554, which suggesting that the stock is 44.574% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 3.43%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AbbVie pays 257.71% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

AbbVie quarterly revenues are $15.1B, which are larger than Moderna quarterly revenues of $956M. AbbVie's net income of -$22M is higher than Moderna's net income of -$1.1B. Notably, AbbVie's price-to-earnings ratio is 77.53x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 5.86x versus 3.30x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.